Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

KERX $5.96 0.5200 +9.56%
NLNK $17.62 1.4050 +8.67%
LOXO $24.98 1.9300 +8.37%
MNKD $1.45 0.1000 +7.41%
CORT $5.05 0.2800 +5.87%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $15.54 -1.7300 -10.02%
PVCT $0.44 -0.0489 -9.98%
BDSI $3.11 -0.2700 -7.99%
VRML $1.30 -0.0900 -6.47%
CERU $3.10 -0.1800 -5.49%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Next Generation ACO Model Letter of Intent Deadline Extended

(ACCC) Apr 21, 2016 - The Centers for Medicare & Medicaid Services (CMS) announced that the deadline for submission of a Next Generation ACO Model Letter of Intent (LOI) has been extended to May 20, 2016.
read article 



A Misguided Experiment?

(ACCCBuzz) Apr 22, 2016 - The noise around drug costs seems to have gotten louder in recent months, with policymakers clamoring for controls on drug pricing, Congressional hearings calling on pharmaceutical executives to testify, and recommendations from the Medicare Payment Advisory Commission (MedPAC) focused on containing Medicare spending in the context of ever-increasing prescription drug costs.
read article 



Laura and Isaac Perlmutter Cancer Center at NYU Langone & the Technion-Israel Institute of Technology Officially Launch Global Cancer Research Initiative

(NYU Langone) Apr 22, 2016 - Melanoma, mesothelioma are the focus of first joint studies.
read press release 



New ASCO Guide for Adjuvant Therapy in Early Breast Cancer

(Medscape Medical News) Apr 22, 2016 - ASCO has issued its first comprehensive clinical guidelines on adjuvant chemotherapy in early breast cancer and targeted adjuvant therapy for HER2-positive disease.
read article (free registration required) 



Helsinn Group Signs Exclusive Agreement With Purdue Pharma Canada For The Distribution And Licensing Rights Of Akynzeo® (Netupitant/Palonosetron Combo)

(Helsinn) Apr 25, 2016 - Helsinn, the Swiss Group focused on building quality cancer care products and Purdue Pharma Canada today announce that they have signed an exclusive agreement for the distribution and licensing of Akynzeo®, the oral fixed combination of netupitant and palonosetron developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).
read corporate press release 



Inside the Development Of Venclexta, AbbVie's New Leukemia Drug

(BioPharma Dive) Apr 22, 2016 - When AbbVie was first moving through testing for its newly approved chronic lymphocytic leukemia (CLL) drug Venclexta, its researchers made a key observation. Patients who had a certain chromosomal abnormality that makes treatment of CLL more difficult were responding equally as well to the drug as other patients.
read article 



FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma

(TheStreet) Apr 25, 2016 - The RTOG 3503 phase 2 trial is the first consortium study to test tumor treating fields therapy.
read article 



Celator® Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS(TM) Compared to Standard Treatment for Acute Myeloid Leukemia (AML)

(Yahoo! Finance) Apr 25, 2016 - Phase 2 study results presented at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting.
read article 



Cell Death Mechanism May—Paradoxically—Enable Aggressive Pancreatic Cells to Live On

(NYU Langone) Apr 25, 2016 - The most aggressive form of pancreatic cancer - often described as one of the hardest malignancies to diagnose and treat -- thrives in the presence of neighboring tumor cells undergoing a particular form of "orchestrated cell death." This is according to a major study recently published in the journal Nature.
read press release 



Chronic Inflammation Of Obesity, Autoimmune Conditions Leads To Imbalanced Blood System And Potential Cancer Risk

(UCCC/Colorado Cancer Blogs) Apr 25, 2016 - Eric Pietras, PhD, shows that chronic exposure to an inflammatory “emergency” signal, interleukin-1, causes blood-forming bone marrow stem cells to produce cells needed to fight infection and repair injury, but at the expense of their own ability to self-renew and maintain a healthy blood system.
read article 



Cancer Risk Remains After Hepatitis B Cleared From Body

(UPI) Apr 22, 2016 - Although hepatitis B has been linked to liver cancer since the early 1980s, a new study by the U.S. Centers for Disease Control suggests clearing the virus does not mitigate the increased risk for liver cancer caused by infection.
read article 



Release Raises False Alarm Over Hep B Meds and Cancer Risk

(Medscape Medical News) Apr 22, 2016 - The long-term nucleoside and nucleotide analogue treatment of patients with chronic hepatitis B is not associated with an increased risk for extrahepatic cancers, according to results from a new study that led to some confusion.
read article (free registration required) 



These Foods Linked to Aggressive Prostate Cancer?

(WebMD/HealthDay News) Apr 22, 2016 - What men eat -- particularly fatty meats and cheese -- may affect how quickly their prostate cancer progresses, a new study suggests.
read article 



Does Sex Protect Men Against Prostate Cancer?

(Reuters Health) Apr 22, 2016 - Men who ejaculate often may have a lower risk of prostate cancer than their peers who don’t do it as frequently, a U.S. study suggests.
read article 



Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(BMS) Apr 5, 2016 - Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum based therapy.
read article 



Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone

(Yahoo! Finance) April 25, 2016 – Merck, a leading science and technology company, today announced that the pivotal Chinese Phase III TAILOR study met its primary endpoint of significantly increasing progression-free survival (PFS) in patients with RAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX chemotherapy, compared with FOLFOX alone.
read article 



Hummingbird Bioscience, Sanofi to Develop Novel Cancer Therapeutics

(BioSpectrum Asia) Apr 22, 2016 - Hummingbird Bioscience, an innovative biotechnology company focused on the discovery and early development of antibody therapeutics, announced a collaboration with Sanofi, a global healthcare leader, to develop novel therapeutic antibodies for the treatment of cancer.
read article 



U.S. Suicide Rate Rising Precipitiously, Especially Among Women

(TIME) Apr 22, 2016 - The rate of Americans ending their own lives has risen to its highest level in decades, according to a new study from the Centers for Disease Control, and the increase is especially pronounced among women.
read article  



New Genome Editing Technique Can Target Single Letters Of DNA Sequence

(Los Angeles Times/Science Now) Apr 21, 2016 - Building off the powerful gene-editing technology known as CRISPR, researchers have created a new tool that can target and change a single letter in a sequence of DNA.
read article (free registration required) 



AstraZeneca Taps Gene Pioneer Venter for Huge Drug-Hunting Sweep

(Reuters) Apr 21, 2016 - AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines.
read article 



Germany Mulls Limiting Prices Drug Firms Can Charge to Health System

(Wall Street Journal) Apr 22, 2016 - The German government is considering limiting the price that drug companies can charge the country’s health care system for their latest medicines—a move that would curtail a lucrative, one-year amnesty from the country’s otherwise strict price controls.
read article (paid subscription required) 



Supreme Court Set To Hear Patent Case That Could Leave Mark On Drug Price Landscape

(KHN Morning Briefing) Apr 22, 2016 - The case being heard next week has nothing directly to do with medicine but insurers and drug makers think the justices' ruling will have repercussions for the generics market. And the Los Angeles Times reports on how pharmacy consolidation impacts drug affordability and KHN writes on patient challenges in accessing some more expensive drugs.
read article 



Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board

(Adaptimmune) Apr 22, 2016 - Adaptimmune Therapeutics plc today announced the appointment of leading immunology, immunotherapy and oncology experts from across the United States and Europe to its newly formed scientific advisory board (SAB).
read corporate press release 



This Company Wants to Cure Pancreatic Cancer Using AI

(Fortune) Apr 22, 2016 - Pancreatic cancer has long vexed researchers. Berg believes artificial intelligence can help.
read article 



Wondering What Caused the Cancer

(New York Times/Well blog) Apr 21, 2016 - Many of my patients ask what caused their cancer. I often wonder the same thing.
read article